AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Mar 2024 07:00 AM
RNS
AstraZeneca to acquire Fusion
14 Mar 2024 07:00 AM
RNS
AstraZeneca to acquire Amolyt
12 Mar 2024 11:00 AM
RNS
Director/PDMR Shareholding
07 Mar 2024 11:00 AM
RNS
Notice of AGM
06 Mar 2024 03:05 PM
RNS
Director/PDMR Shareholding
06 Mar 2024 03:00 PM
RNS
Director/PDMR Shareholding
04 Mar 2024 07:00 AM
RNS
EMA validates Dato-DXd MAAs for NSQ NSCLC and BC
01 Mar 2024 03:00 PM
RNS
Total Voting Rights
26 Feb 2024 07:00 AM
RNS
Voydeya recommended for EU approval
22 Feb 2024 01:15 PM
RNS
Acquisition of Gracell completed
22 Feb 2024 11:00 AM
RNS
Director/PDMR Shareholding
22 Feb 2024 07:00 AM
RNS
AstraZeneca prices a $5bn bond offering
21 Feb 2024 07:00 AM
RNS
Filing of Form 20-F with SEC
20 Feb 2024 11:00 AM
RNS
Annual Financial Report
19 Feb 2024 03:00 PM
RNS
AstraZeneca completes acquisition of Icosavax
19 Feb 2024 07:10 AM
RNS
Tagrisso plus chemo approved in US for lung cancer
19 Feb 2024 07:05 AM
RNS
FDA accepts Dato-DXd BLA for nonsquamous NSCLC
19 Feb 2024 07:00 AM
RNS
Tagrisso improved PFS in Stage III lung cancer
08 Feb 2024 07:00 AM
RNS
Final Results
01 Feb 2024 03:00 PM
RNS
Total Voting Rights
02 Jan 2024 03:00 PM
RNS
Total Voting Rights
27 Dec 2023 07:00 AM
RNS
AstraZeneca acquires Gracell
22 Dec 2023 07:00 AM
RNS
Wainua (eplontersen) granted first US FDA approval
14 Dec 2023 03:00 PM
RNS
Director/PDMR Shareholding
12 Dec 2023 07:05 AM
RNS
AstraZeneca to acquire Icosavax
01 Dec 2023 03:05 PM
RNS
Block listing Interim Review
01 Dec 2023 03:00 PM
RNS
Total Voting Rights
01 Dec 2023 07:00 AM
RNS
Discontinuation of two CRYSTALIZE evidence trials
23 Nov 2023 03:00 PM
RNS
Director/PDMR Shareholding
17 Nov 2023 07:00 AM
RNS
Truqap approved in US for HR+ breast cancer
14 Nov 2023 07:05 AM
RNS
Update on PACIFIC-2 Phase III trial for Imfinzi
09 Nov 2023 03:00 PM
RNS
Director Declaration
09 Nov 2023 07:10 AM
RNS
Imfinzi combination improves PFS in liver cancer
09 Nov 2023 07:05 AM
RNS
Agreement with Eccogene for clinical stage GLP-1RA
09 Nov 2023 07:00 AM
RNS
9M and Q3 2023 results
01 Nov 2023 03:00 PM
RNS
Total Voting Rights
01 Nov 2023 07:00 AM
RNS
AstraZeneca cell & gene therapy deal w/ Cellectis
03 Oct 2023 07:00 AM
RNS
AstraZeneca settles Nexium liability litigations
02 Oct 2023 03:00 PM
RNS
Total Voting Rights
22 Sep 2023 07:00 AM
RNS
Dato-DXd improved PFS in breast cancer
20 Sep 2023 07:00 AM
RNS
Alexion completes Pfizer gene therapy agreement
15 Sep 2023 03:00 PM
RNS
Enhertu recommended in EU for HER2-mutant NSCLC
11 Sep 2023 04:00 PM
RNS
Fasenra Phase III EGPA trial met primary endpoint
06 Sep 2023 07:00 AM
RNS
Update on US review of Ultomiris for NMOSD
01 Sep 2023 03:00 PM
RNS
Total Voting Rights
01 Aug 2023 03:00 PM
RNS
Total Voting Rights
28 Jul 2023 07:05 AM
RNS
Alexion enters gene therapy agreement with Pfizer
28 Jul 2023 07:00 AM
RNS
Half-year Report
17 Jul 2023 06:10 PM
RNS
Beyfortus approved in US for infant RSV prevention
03 Jul 2023 03:00 PM
RNS
Total Voting Rights
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings